Increased toxicities in children with Burkitt lymphoma treated with rituximab: Experience from a tertiary cancer center in India

Rituximab was associated with increased toxicities and toxic deaths in our patients. The potential immunomodulatory effect of rituximab and increased susceptibility to infections in patients from LMICs have to be carefully considered while choosing this drug in the treatment of BL in resource-constrained settings.